Pages that link to "Q40298283"
The following pages link to c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling (Q40298283):
Displaying 20 items.
- Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response (Q28239216) (← links)
- Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression (Q28478132) (← links)
- RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells (Q33398834) (← links)
- Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage (Q33527429) (← links)
- c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients (Q33821504) (← links)
- Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC. (Q35071356) (← links)
- Targeting of the MYCN protein with small molecule c-MYC inhibitors (Q35173570) (← links)
- Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. (Q36246412) (← links)
- Bioelectronome. Integrated approach to receptor chemistry, radicals, electrochemistry, cell signaling, and physiological effects based on electron transfer (Q36948324) (← links)
- PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization (Q37038041) (← links)
- The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy (Q37728617) (← links)
- MYC in oncogenesis and as a target for cancer therapies (Q37732974) (← links)
- High-dose etoposide in allogeneic stem cell transplantation (Q38051016) (← links)
- Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development (Q38088759) (← links)
- C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells (Q38965179) (← links)
- Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. (Q45180255) (← links)
- Cytotoxicity and antiangiogenic activity of grandisin. (Q50449106) (← links)
- Regulation of calpain activity by c-Myc through calpastatin and promotion of transformation in c-Myc-negative cells by calpastatin suppression. (Q53472176) (← links)
- Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy. (Q54977126) (← links)
- The Biological Significance and Regulatory Mechanism of c-Myc Binding Protein 1 (MBP-1) (Q60919628) (← links)